Bicycle Therapeutics plc (NASDAQ:BCYC) Shares Sold by Bellevue Group AG

Bellevue Group AG lowered its stake in Bicycle Therapeutics plc (NASDAQ:BCYC) by 37.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 12,500 shares of the company’s stock after selling 7,500 shares during the period. Bellevue Group AG’s holdings in Bicycle Therapeutics were worth $311,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of BCYC. China Universal Asset Management Co. Ltd. raised its stake in Bicycle Therapeutics by 489.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,001 shares of the company’s stock valued at $72,000 after buying an additional 3,322 shares in the last quarter. PNC Financial Services Group Inc. bought a new position in Bicycle Therapeutics during the fourth quarter worth $137,000. PDS Planning Inc bought a new stake in Bicycle Therapeutics during the first quarter valued at $210,000. Concurrent Investment Advisors LLC acquired a new stake in shares of Bicycle Therapeutics during the first quarter worth $543,000. Finally, Woodstock Corp raised its holdings in shares of Bicycle Therapeutics by 16.3% during the first quarter. Woodstock Corp now owns 24,981 shares of the company’s stock worth $622,000 after purchasing an additional 3,502 shares during the period. Institutional investors and hedge funds own 86.15% of the company’s stock.

Insider Activity at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,194 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $19.64, for a total transaction of $62,730.16. Following the sale, the chief executive officer now directly owns 384,076 shares in the company, valued at approximately $7,543,252.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 4,555 shares of company stock worth $89,460 in the last 90 days. Corporate insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Stock Performance

Shares of BCYC traded down $1.16 during mid-day trading on Monday, reaching $23.35. 34,756 shares of the company’s stock traded hands, compared to its average volume of 332,441. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.42 and a current ratio of 10.42. The business’s 50-day moving average price is $22.07 and its 200-day moving average price is $22.13. The stock has a market capitalization of $998.89 million, a P/E ratio of -5.35 and a beta of 0.94. Bicycle Therapeutics plc has a 12 month low of $12.54 and a 12 month high of $27.24.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, May 2nd. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.63. Bicycle Therapeutics had a negative return on equity of 49.35% and a negative net margin of 404.14%. The firm had revenue of $19.53 million for the quarter, compared to the consensus estimate of $6.06 million. The company’s revenue was up 298.9% compared to the same quarter last year. Equities analysts predict that Bicycle Therapeutics plc will post -4.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, May 3rd. Needham & Company LLC reiterated a “buy” rating and set a $43.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.86.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.